CO6700862A2 - Polipéptidos derivados de la il-2 con actividad agonista para la terapia del cáncer e infecciones crónicas. - Google Patents
Polipéptidos derivados de la il-2 con actividad agonista para la terapia del cáncer e infecciones crónicas.Info
- Publication number
- CO6700862A2 CO6700862A2 CO13103448A CO13103448A CO6700862A2 CO 6700862 A2 CO6700862 A2 CO 6700862A2 CO 13103448 A CO13103448 A CO 13103448A CO 13103448 A CO13103448 A CO 13103448A CO 6700862 A2 CO6700862 A2 CO 6700862A2
- Authority
- CO
- Colombia
- Prior art keywords
- polypeptides
- relates
- present
- cancer
- therapy
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 230000000694 effects Effects 0.000 title abstract 3
- 208000037581 Persistent Infection Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 210000003289 regulatory T cell Anatomy 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a polipéptidos que comparten secuencia primaria con la L-2 humana, excepto porque varios aminoácidos han sido mutados. Las mutaciones introducidas reducen sustancialmente la capacidad de estos polipéptidos para estimular in vitro e in vivo a las células T reguladoras (T CD4+CD25+FoxP3+) y le confieren una mayor eficacia en la terapia de tumores trasplantables murinos. Además, las aplicaciones terapéuticas de estas variantes, solas o en combinación con vacunas, para la terapia de enfermedades como el cáncer o infecciones donde la actividad de las células T reguladoras (Tregs) es relevante. En otro aspecto la presente invención se relaciona con las composiciones farmacéuticas que comprenden como principio activo los polipéptidos divulgados. Por último, la presente invención se relaciona con el uso terapéutico de los polipéptidos y composiciones farmacéuticas divulgados dado su efecto modulador del sistema inmune sobre patologías como cáncer y enfermedades infecciosas crónicas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2010000216A CU23923B1 (es) | 2010-11-12 | 2010-11-12 | Polipéptidos derivados de la il-2 con actividad agonista |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6700862A2 true CO6700862A2 (es) | 2013-06-28 |
Family
ID=45350376
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO13103448A CO6700862A2 (es) | 2010-11-12 | 2013-04-23 | Polipéptidos derivados de la il-2 con actividad agonista para la terapia del cáncer e infecciones crónicas. |
Country Status (22)
Country | Link |
---|---|
US (1) | US9206243B2 (es) |
EP (1) | EP2639241B1 (es) |
JP (1) | JP5761831B2 (es) |
KR (1) | KR101559330B1 (es) |
CN (1) | CN103201284B (es) |
AR (1) | AR083858A1 (es) |
AU (1) | AU2011328688B2 (es) |
BR (1) | BR112013010127B1 (es) |
CA (1) | CA2814814C (es) |
CL (1) | CL2013001107A1 (es) |
CO (1) | CO6700862A2 (es) |
CU (1) | CU23923B1 (es) |
EA (1) | EA026022B1 (es) |
ES (1) | ES2543915T3 (es) |
HK (1) | HK1182403A1 (es) |
IL (1) | IL226221B (es) |
MX (1) | MX346222B (es) |
MY (1) | MY171356A (es) |
PE (1) | PE20140382A1 (es) |
TW (1) | TWI488864B (es) |
UA (1) | UA106318C2 (es) |
WO (1) | WO2012062228A2 (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
EP3102595B1 (en) | 2014-02-06 | 2018-11-07 | F.Hoffmann-La Roche Ag | Interleukin-2 fusion proteins and uses thereof |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
SI3134127T1 (sl) * | 2014-04-25 | 2020-06-30 | Rinat Neuroscience Corp. | Konjugati zdravil s protitelesi z visoko stopnjo zdravila |
HUE051414T2 (hu) | 2014-08-11 | 2021-03-01 | Delinia Inc | Módosított IL-2 változatok, amelyek szelektíven aktiválnak regulátor T sejteket, autoimmun betegségek kezelésére |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
RU2756236C2 (ru) | 2016-06-20 | 2021-09-28 | Кимаб Лимитед | PD-L1 специфические антитела |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
AU2017357042A1 (en) * | 2016-11-10 | 2019-05-30 | Board Of Regents, The University Of Texas System | Immunotherapeutic tumor treatment method |
CU24483B1 (es) * | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
SG11201909949XA (en) | 2017-05-24 | 2019-11-28 | Pandion Therapeutics Inc | Targeted immunotolerance |
US11542312B2 (en) * | 2017-06-19 | 2023-01-03 | Medicenna Therapeutics, Inc. | IL-2 superagonists in combination with anti-PD-1 antibodies |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
KR20200100098A (ko) | 2017-12-19 | 2020-08-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
US20210260163A1 (en) * | 2018-03-09 | 2021-08-26 | AskGene Pharma, Inc. | Novel cytokine prodrugs |
CU24554B1 (es) * | 2018-05-07 | 2021-11-04 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
BR112020023167A2 (pt) | 2018-05-14 | 2021-02-09 | Werewolf Therapeutics, Inc. | polipeptídeos de citocina ativáveis e métodos de uso destes |
EP3794024B1 (en) | 2018-05-14 | 2023-05-10 | Werewolf Therapeutics, Inc. | Activatable interleukin-2 polypeptides and methods of use thereof |
US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
BR112020015030A2 (pt) * | 2018-09-17 | 2021-03-16 | Gi Innovation, Inc. | Proteína de fusão compreendendo a proteína il-2 e a proteína cd80 e uso da mesma |
JP7479383B2 (ja) | 2018-09-27 | 2024-05-08 | エクシリオ デベロップメント, インコーポレイテッド | マスクされたサイトカインポリペプチド |
CA3117853A1 (en) * | 2018-10-29 | 2020-05-07 | 1Globe Biomedical Co., Ltd. | Novel rationally designed protein compositions |
TW202034945A (zh) | 2018-12-21 | 2020-10-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種人白細胞介素2變體或其衍生物 |
CU20190021A7 (es) * | 2019-03-15 | 2020-10-20 | Centre Hospitalier Univ Vaudois | Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva |
CN114450022A (zh) | 2019-05-14 | 2022-05-06 | 狼人治疗公司 | 分离部分及其使用方法 |
TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向MAdCAM之免疫耐受性 |
US20220305124A1 (en) * | 2019-06-05 | 2022-09-29 | Emory University | Photolysis to Unlock Caged Protein Therapeutics |
KR20220020879A (ko) | 2019-06-12 | 2022-02-21 | 에스크진 파마, 아이엔씨. | 새로운 il-15 프로드럭 및 이를 사용하는 방법 |
KR20220034115A (ko) * | 2019-06-14 | 2022-03-17 | 큐진 인크. | 암 치료용 신규한 인터루킨-2 변이체 |
US20220356221A1 (en) | 2019-09-28 | 2022-11-10 | AskGene Pharma, Inc. | Cytokine prodrugs and dual-prodrugs |
US20210187027A1 (en) | 2019-12-20 | 2021-06-24 | Regeneron Pharmaceuticals, Inc. | Novel il2 agonists and methods of use thereof |
AU2021206449A1 (en) | 2020-01-10 | 2022-07-21 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
KR102653906B1 (ko) | 2020-01-14 | 2024-04-03 | 신테카인, 인크. | 편향된 il2 뮤테인 방법 및 조성물 |
EP4107187A1 (en) | 2020-02-21 | 2022-12-28 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
AU2021259426B2 (en) | 2020-04-22 | 2024-05-16 | Merck Sharp & Dohme Corp. | Human interleukin-2 conjugates biased for the interleukin-2 receptor beta gammac dimer and conjugated to a nonpeptidic, water-soluble polymer |
JPWO2022059794A1 (es) * | 2020-09-18 | 2022-03-24 | ||
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
US20230398183A1 (en) | 2020-11-13 | 2023-12-14 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising human interleukin 2 variant or derivative thereof and use thereof |
KR20240041378A (ko) | 2021-07-09 | 2024-03-29 | 브라이트 피크 테라퓨틱스 아게 | 체크포인트 억제제와 il-2의 접합체 및 이의 용도 |
US20230201365A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Modified cd20 antibodies and uses thereof |
EP4366778A1 (en) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Antibody conjugates and manufacture thereof |
US20240158537A1 (en) | 2021-07-09 | 2024-05-16 | Bright Peak Therapeutics Ag | Synthetic il-7 and il-7 immunocytokines |
EP4357357A1 (en) | 2021-07-30 | 2024-04-24 | Yunquan Biotechnology (Beijing) Co., Ltd. | Human interleukin-2 variant and use thereof |
CU20210104A7 (es) | 2021-12-21 | 2023-07-12 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2 |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
US20240132563A1 (en) | 2022-02-23 | 2024-04-25 | Bright Peak Therapeutics Ag | Bifunctional cytokine compositions |
WO2023180527A1 (en) | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4853332A (en) | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
FR2624741B1 (fr) * | 1987-12-21 | 1991-06-28 | Pasteur Institut | Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire |
ATE147633T1 (de) * | 1988-10-27 | 1997-02-15 | Univ Minnesota | Immunhilfsmittel aus liposome enthaltend lymphokin il -2 |
US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
BR0214650A (pt) | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
CN1609227A (zh) * | 2003-10-24 | 2005-04-27 | 中国科学院沈阳应用生态研究所 | 一种白介素-4突变基因il-4-13及其制备和应用 |
JP5022216B2 (ja) * | 2004-06-04 | 2012-09-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 自己炎症性疾患を処置するためのil−1アンタゴニストを使用する方法 |
CA2656700A1 (en) * | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
US8906356B2 (en) * | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
DE102008023820A1 (de) * | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
JP5766124B2 (ja) * | 2009-01-21 | 2015-08-19 | アムジェン インコーポレイテッド | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
-
2010
- 2010-11-12 CU CU2010000216A patent/CU23923B1/es active IP Right Grant
-
2011
- 2011-11-10 UA UAA201307450A patent/UA106318C2/ru unknown
- 2011-11-10 KR KR1020137012452A patent/KR101559330B1/ko active IP Right Grant
- 2011-11-10 ES ES11797102.8T patent/ES2543915T3/es active Active
- 2011-11-10 BR BR112013010127-0A patent/BR112013010127B1/pt active IP Right Grant
- 2011-11-10 WO PCT/CU2011/000007 patent/WO2012062228A2/es active Application Filing
- 2011-11-10 EP EP11797102.8A patent/EP2639241B1/en active Active
- 2011-11-10 US US13/885,021 patent/US9206243B2/en active Active
- 2011-11-10 EA EA201390681A patent/EA026022B1/ru not_active IP Right Cessation
- 2011-11-10 CA CA2814814A patent/CA2814814C/en active Active
- 2011-11-10 AU AU2011328688A patent/AU2011328688B2/en active Active
- 2011-11-10 JP JP2013538062A patent/JP5761831B2/ja active Active
- 2011-11-10 PE PE2013001054A patent/PE20140382A1/es not_active Application Discontinuation
- 2011-11-10 MY MYPI2013700752A patent/MY171356A/en unknown
- 2011-11-10 MX MX2013005250A patent/MX346222B/es active IP Right Grant
- 2011-11-10 CN CN201180054156.2A patent/CN103201284B/zh active Active
- 2011-11-11 TW TW100141299A patent/TWI488864B/zh active
- 2011-11-11 AR ARP110104234A patent/AR083858A1/es active IP Right Grant
-
2013
- 2013-04-23 CL CL2013001107A patent/CL2013001107A1/es unknown
- 2013-04-23 CO CO13103448A patent/CO6700862A2/es unknown
- 2013-05-07 IL IL226221A patent/IL226221B/en active IP Right Grant
- 2013-08-21 HK HK13109794.4A patent/HK1182403A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6700862A2 (es) | Polipéptidos derivados de la il-2 con actividad agonista para la terapia del cáncer e infecciones crónicas. | |
CU23734A1 (es) | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas | |
MD4577B1 (ro) | Compoziţii masticabile de uz veterinar care conţin agent activ izoxazolinic şi utilizarea acestora în tratamentul sau prevenirea unei infestări sau infecţii parazitare | |
ECSP14012676A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
IN2012DN06720A (es) | ||
EA201101518A1 (ru) | Фармацевтическая композиция для применения в медицинской и ветеринарной офтальмологии | |
BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
MY188139A (en) | Sodium channel modulators for the treatment of pain | |
MX363007B (es) | Uso de n-acetil-5-metoxi-triptamina o analogos de la misma para potenciar el mecanismo de implantacion del embrion, y composiciones y medios de cultivo relacionados. | |
BR112013008601A8 (pt) | Formulações de emulsão de clevidipina contendo agentes antimicrobianos | |
BR112012016853A2 (pt) | "composições farmacêuticas para administração oral de peptídeos de insulina". | |
EA201391119A1 (ru) | Системы доставки наночастиц, их получение и применение | |
BR112014011981A8 (pt) | Formulações farmacêuticas sólidas orais, seus processos de preparação e usos | |
CL2012001836A1 (es) | Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros. | |
EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
CR20140475A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
TR200900878A2 (tr) | Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar | |
UY35091A (es) | Formulaciones de liberacion modificada para oprozomib | |
BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
CO2017003263A2 (es) | Composición farmacéutica basadas en anamorelina que tienen actividad sobre caquexia causada por cáncer | |
CO2019014671A2 (es) | Agentes de iarn para la inhibición de la expresión de alfa-enac y métodos de uso | |
BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
MX2019002657A (es) | Combinaciones con un peptido con esqueleto ciclado. | |
TN2013000151A1 (en) | Polypeptides derived from il-2 having agonist activity for the therapy of cancer and chronic infections | |
TR201201022A2 (tr) | Akciğer hastalıkları, karaciğer hastalıkları ve çeşitli enfeksiyonların semptomatik ve/veya terapötik tedavisinde kullanılan farmasötik bileşimler. |